Trends in the outpatient treatment of atrial fibrillation in the USA from 2001 to 2010

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 5, 2014, Pages 539-547

  Desai, Amarsinh M ^a   Cavanaugh, Teresa M ^a   Desai, Vibha C A ^a   Heaton, Pamela C ^a   Kelton, Christina M L ^a,b  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Atrial fibrillation; Beta blockers; Calcium channel blockers; Outpatient treatment; Pharmacoepidemiology; Rate control drugs; Rhythm control medications

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; VERAPAMIL; ANTIARRHYTHMIC AGENT;

AGE; AGED; ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL; UNITED STATES; AMBULATORY CARE; ATRIAL FIBRILLATION; CLINICAL PRACTICE; HEALTH CARE SURVEY; MIDDLE AGED; OUTPATIENT; STATISTICAL MODEL; TRENDS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEALTH CARE SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 84898049432     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3605     Document Type: Article

References (34)

1. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57(11): e101-e198.
2. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on atithrombotic and thrombolytic therapy. Chest 2004; 126(3): 429S-456S.
3. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009; 84(3): 234-242.
4. McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139(12): 1018-1033.
5. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342(13): 913-920.
6. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352(18): 1861-1872.
7. Prystowsky EN, Benson Jr DW, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93(6): 1262-1277.
8. Singh B. The mechanism of action of calcium antagonists relative to their clinical applications. Brit J Clin Pharmacol 2012; 21(S2): 109S-121S.
9. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003; 91(6): 15-26.
10. O'Brien K, Alexander E, Patel L. Efficacy and safety of pharmacological options for rate control in atrial fibrillation. AACN Adv Crit Care 2012; 23(2): 120-125.
11. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. New Engl J Med 2002; 347(23): 1834-1840.
12. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41(10): 1690-1696.
13. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004; 126(2): 476-486.
14. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109(16): 1973-1980.
15. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356(9244): 1789-1794.
16. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll of Cardiol 2004; 43(2): 241-247.
17. Wyse D, Waldo A, DiMarco J, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: a comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347(23): 1825-1833.
18. Nikolaidou T, Channer K. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J 2009; 85(1004): 303-312.
19. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004; 164(1): 55-60.
20. National Center for Health Statistics. NAMCS micro-data file documentation 2010. Available at ftp://ftp.cdc.gov/pub/Health_statistics/NCHs/Dataset_Documentation/NAMCS/doc2010.pdf [2 March 2014].
21. National Center for Health Statistics. NHAMCS micro-data file documentation 2010. Available at ftp://ftp.cdc.gov/pub/Health_statistics/NCHs/Dataset_Documentation/NAMCS/doc2010.pdf [2 March 2014].
22. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc; March 2005.
23. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens 2012; 30(2): 239-252.
24. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. Royal College of Physicians: London, 2006.
25. Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation: rhythm vs rate control drug treatment. Arch Intern Med 2012; 172(13): 997-1004.
26. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993; 14: 18-25.
27. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Inter J Cardiol 2008; 127(3): 299-306.
28. Barnes P. Clinical studies with calcium antagonists in asthma. Brit J Clin Pharmacol 2012; 20(S2): 289S-298S.
29. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298(11): 1312-1322.
30. Abraham WT, Chin FMH, Feldman AM, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol 2009; 53(15): e1-90.
31. Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy 1997; 17(6): 1238-1245.
32. Reiffel JA, Kowey PR, Myerburg R, et al. Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am J Cardiol 2010; 105(8): 1122-1129.
33. Steinberg BA, Holmes DN, Ezekowitz MD, et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 2013; 165(4): 622-629.
34. Piccini JP, Mi X, DeWald TA, Go AS, Hernandez AF, Curtis LH. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm 2012; 9(9): 1403-1408.